Patients with STEMI undergoing primary PCI continue to have worse outcomes and higher mortality, bleeding, stent thrombosis, and secondary cardiovascular events. Patterns and controversies unique to primary PCI for STEMI, such as whether radial access benefits patients and what the roles should be for complete revascularization and thrombus aspiration, are evolving. Three trials presented at ACC 2015, combining over 30,000 patients, provide insight into some of these issues. The TOTAL study addresses routine thrombus aspiration, while DANAMI3-PRIMULTI looks at multivessel revascularization and delayed stenting. New information on long-term use of dual antiplatelet therapy comes from PEGASUS-TIMI 54, which evaluated the use of ticagrelor with aspirin for secondary prevention in high-risk patients 1 to 3 years after MI. This webcast will summarize the data, answer audience questions, and provide context through panel discussion on the TOTAL, PEGASUS-TIMI 54, and DANAMI3-PRIMULTI studies.
Click Here to access this CME Program
June 8th, 2015
December 8th, 2015